IKNA

Ikena Oncology Inc

NASDAQ

Add Alert

IKNA

Ikena Oncology Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Monksdream PremiumMember

03/17/24 1:19 PM

Post #12

IKNA under $2=

Monksdream PremiumMember

02/24/24 2:41 PM

Post #11

Re: #10: @herbied47 - $196.9M in cash, cash equivalents, and marketable securities,

IKNA under $2

herbied47

11/10/23 12:22 PM

Post #10

$196.9M in cash, cash equivalents, and marketable securities, which it said would support operations well into 2026. $5.40 a share in cash
Market cap 37 million as of now. Price targets still between $8 and $11. Lots of upcoming catalyst Bullish

Bullish

herbied47

11/10/23 12:16 PM

Post #9

Way over sold! https://finance.yahoo.com/news/broker-revenue-forecasts-ikena-oncology-100336585.html

Bullish

Tacostocks Free

11/09/23 5:36 PM

Post #8

Re: #7: @Money hunt - what happened here my short friend

It went down, because it didnt have the backing of Money hunt...

Money hunt Free

11/09/23 5:31 PM

Post #7

Re: #6: @Tacostocks - Aged like milk eh

what happened here my short friend

Tacostocks Free

11/09/23 4:55 PM

Post #6

Re: #4: @Tartiaboy - This is a very inactive board, but IKNA

Aged like milk eh

AJ Freely

08/08/23 7:57 AM

Post #5

$IKNA - 👆Up 5.2% Pre-Market/ Current Price $5
To Acquire & Merge w/ Pionyr Immunotherapeutics

Tartiaboy

01/29/23 12:40 PM

Post #4

This is a very inactive board, but IKNA is worth keeping an eye on. I currently do not own any but am interested enough to follow it. Right now my biggest interest is in IKNA's new molecule IK-595- the RAF:MEK clamp. They intend to file and IND application in 2H2023. I see very big future potential for IK-595 and want to see how IKNA develops it's early clinical plan.

I am not too familiar with there lead drug so I am neutral regarding it.

TrendTrade2016 PremiumMember

05/06/22 11:25 AM

Post #3

IKNA look at this beast

TrendTrade2016 PremiumMember

05/06/22 11:17 AM

Post #2

IKNA monster

crudeoil24 PremiumMember

03/26/21 11:56 AM

Post #1

Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.